Firas El Chaer, MD, University of Virginia, Charlottesville, VA, discusses the role of post-transplant maintenance therapy in acute myeloid leukemia (AML), highlighting data from key clinical trials including SORMAIN (EudraCT 2010-018539-16), RADIUS (NCT01883362), and BMT 1506. Whilst the SORMAIN trial showed a significant benefit in overall survival (OS) for patients with FLT3+ AML treated with sorafenib maintenance, the RADIUS trial did not report any improvements for patients treated with midostaurin. Data from the BMT 1506 trial evaluating gilteritinib in the maintenance setting is eagerly awaited. Dr El Chaer also mentions a study assessing the use of azacitidine in the maintenance setting. According to Dr El Chaer, maintenance therapy remains important in certain patient groups, including patients with high-risk disease, patients who are measurable residual disease (MRD)-positive prior to stem cell transplantation, or patients treated with a reduced-intensity conditioning (RIC) regimen. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

свернуть